The synergistic combination of NLRC3 inhibitors, cGAS-STING pathway agonists, and immune checkpoint inhibitors holds particular promise for enhancing anti-tumor immune responses on multiple fronts. The gene discussed is NLRC3; the disease is neoplasm.